CTLA‐4‐targeting monoclonal antibodies (MoAbs) activate the T cells in the gut, leading to colitis characterised by elevated CD4+ effector and regulatory T cells (Tregs), accompanied by significant changes in Treg gene expression.54 This evidence concerns the gene CTLA4 and colitis.